Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: A phase 1b, multiple-ascending dose study

By sjmartinez • February 13, 2024

Veverka KA, Thng STG, Silverberg JI, Armstrong AW, Menezes J, Kaoukhov A, Blauvelt A. Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: A phase 1b, multiple-ascending dose study. J Am Acad Dermatol. 2024 Mar;90(3):504-511. doi: 10.1016/j.jaad.2023.10.026. Epub 2023 Oct 20. PMID: 37866456.

Tags: atopic dermatitis, Dermatology, EASI, eblasakimab, IL-13, IL-4, moderate-to-severe AD, pruritus, Publications, type 2 inflammation

Increased mitochondrial mutation heteroplasmy induces aging phenotypes in pluripotent stem cells and their differentiated progeny

Vandiver AR, Torres A Jr, Sanden A, Nguyen TL, Gasilla J, Doan MT, Martirosian V, Hoang A, Wanagat J, Teitell MA. Increased mitochondrial mutation heteroplasmy[...]

Update on Absorbable Facial Thread Lifts

Riopelle AM, Geisler AN, Eber A, Dover JS. Update on Absorbable Facial Thread Lifts. Dermatol Surg. 2024 Dec 11. doi: 10.1097/DSS.0000000000004521. Epub ahead of print.[...]

Unusual Cutaneous Metastasis in a Patient with Cholangiocarcinoma

Dong E, Yashar S, Mandelkern M, Kaunitz J. Unusual Cutaneous Metastasis in a Patient with Cholangiocarcinoma. Dig Dis Sci. 2024 Dec 11. doi: 10.1007/s10620-024-08775-1. Epub[...]